Gökhan Gürses

---

Gökhan Gürses was born in 1988. He graduated from Kırıkkale University, Faculty of Dentistry, in 2013. He completed his specialty training at Necmettin Erbakan University, Faculty of Dentistry, Oral and Maxillofacial Surgery Department in 2019. After that, he worked as a Specialist at Afyonkarahisar Public Oral and Dental Health Center. Since 2020, he has been working as an Assistant Professor at Selcuk University Faculty of Dentistry, Department of Maxillofacial Surgery. Gökhan Gürses is a member of AÇBID since 2015.

Current Treatment and Management Strategies for MRONJ

Antiresorptive and antiangiogenetic medications can cause MRONJ. Among the drugs that cause MRONJ, the most popular are bisphosphonate and denosumab. MRONJ management is a controversial topic due to its multifactorial nature. There is no definitive and single treatment method. Researchers have tried different methods or products to prevent, manage or treat. These are in a wide range from conservative to radical. Also, adjuvant therapies are defined in the literature. MRONJ is an exhausting and challenging chronic condition for the physician and the patient. Both lead and adjuvant therapies are directed toward the pathophysiology of MRONJ, as in almost all diseases. Inhibition of osteoclasts, inflammation, and infection, inhibition of angiogenesis, immune dysfunction, and genetics are potential pathophysiological hypotheses. In addition to these, systemic and local risk factors act as predisposing factors. In this presentation, I will mention the short history of MRONJ, which has been going on from the past to the present, its definition, staging, pathophysiology, and the current treatment and prevention methods widely used.